Swiss National Bank lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,475,273 shares of the medical research company’s stock after selling 74,660 shares during the period. Swiss National Bank’s holdings in Amgen were worth $482,872,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Principal Securities Inc. raised its stake in Amgen by 7.6% in the fourth quarter. Principal Securities Inc. now owns 17,665 shares of the medical research company’s stock valued at $5,782,000 after buying an additional 1,246 shares during the period. Connecticut Wealth Management LLC raised its stake in Amgen by 11.0% in the fourth quarter. Connecticut Wealth Management LLC now owns 5,761 shares of the medical research company’s stock valued at $1,886,000 after buying an additional 572 shares during the period. Aviva PLC raised its stake in Amgen by 5.5% in the fourth quarter. Aviva PLC now owns 450,901 shares of the medical research company’s stock valued at $147,584,000 after buying an additional 23,465 shares during the period. Mosley Wealth Management bought a new stake in Amgen in the fourth quarter valued at approximately $419,000. Finally, Founders Financial Alliance LLC raised its stake in Amgen by 32.7% in the fourth quarter. Founders Financial Alliance LLC now owns 2,043 shares of the medical research company’s stock valued at $669,000 after buying an additional 504 shares during the period. Institutional investors own 76.50% of the company’s stock.
Insider Activity at Amgen
In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.85% of the company’s stock.
Amgen News Roundup
- Positive Sentiment: Amgen presented new Phase 3 VESALIUS-CV data showing Repatha significantly reduced cardiovascular risk in high-risk diabetes patients, strengthening the case for its cardio-metabolic franchise. Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now
- Positive Sentiment: Investor coverage remains bullish, with articles highlighting Amgen as a potential value stock and pointing to attractive valuation metrics versus expected earnings growth. Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
- Positive Sentiment: Amgen updated investors on its Phase 3 MARITIME-SWITCH trial, which targets GLP-1 switchers in obesity, supporting its strategy to win share in a rapidly expanding market. Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
- Neutral Sentiment: Several market commentary pieces discussed Amgen as a large-cap value or healthcare exposure idea, but these are mostly sentiment-driven rather than immediate fundamentals. Healthcare ETFs: From Broad Exposure to Big Breakthroughs
- Negative Sentiment: Recent trading-day coverage noted Amgen underperformed the broader market, suggesting some short-term profit-taking or volatility even as the longer-term story improves. Amgen Inc. stock underperforms Wednesday when compared to competitors
Amgen Price Performance
Amgen stock opened at $354.06 on Friday. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The stock’s 50 day moving average is $340.94 and its 200-day moving average is $345.65. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a market capitalization of $191.09 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 3.39 and a beta of 0.42.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the business earned $4.90 earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts expect that Amgen Inc. will post 22.38 EPS for the current year.
Wall Street Analysts Forecast Growth
AMGN has been the topic of several research analyst reports. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Truist Financial upped their price objective on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Morgan Stanley upped their price objective on Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday. Finally, UBS Group upped their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $354.12.
Check Out Our Latest Report on AMGN
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Read More
- Five stocks we like better than Amgen
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
